Fine-tuning CARs for best performance.

Cancer Cell

University College London (UCL) Great Ormond Street Institute of Child Health, London, UK; UCL Cancer Institute, London, UK. Electronic address:

Published: January 2022

AI Article Synopsis

  • Chimeric antigen receptors (CARs) can be engineered to redirect T cells to target specific surface antigens in cancer therapy.
  • Researchers, led by Heitzeneder et al., focused on enhancing CAR designs to effectively target low-density antigens, specifically cerebroglycan (GPC2).
  • Their optimized CAR design demonstrated strong effectiveness in pre-clinical studies using neuroblastoma models.

Article Abstract

Chimeric antigen receptors (CARs) allow redirection of T cells against any surface antigen. However, CARs require optimization to achieve activity against low-density antigens. Heitzeneder et al. perform an iterative adjustment of CAR components to reach a design for targeting cerebroglycan (GPC2) that shows potent pre-clinical activity in neuroblastoma models.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2021.12.010DOI Listing

Publication Analysis

Top Keywords

fine-tuning cars
4
cars best
4
best performance
4
performance chimeric
4
chimeric antigen
4
antigen receptors
4
receptors cars
4
cars allow
4
allow redirection
4
redirection t cells
4

Similar Publications

The Ideal Plant Architecture 1 (IPA1) transcription factor promotes rice yield and immunity through phosphorylation at its amino acid residue Ser163 as a switch. Although phosphorylated IPA1 mimic, IPA1(S163D), directly targets the promoter of immune response gene WRKY45, it cannot activate its expression. Here, we identified a co-activator of IPA1(S163D), a RING-finger E3 ligase IPA1 interactor 7 (IPI7), which fine-tunes the transcriptional activity of IPA1 to timely promote plant immunity and simultaneously maintain growth for yield.

View Article and Find Full Text PDF

Fine-tuning the antigen sensitivity of CAR T cells: emerging strategies and current challenges.

Front Immunol

December 2023

Leibniz Institute for Immunotherapy, Division of Genetic Immunotherapy, Chair Genetic Immunotherapy, University Regensburg, Regensburg, Germany.

Chimeric antigen receptor (CAR) T cells are "living drugs" that specifically recognize their target antigen through an antibody-derived binding domain resulting in T cell activation, expansion, and destruction of cognate target cells. The FDA/EMA approval of CAR T cells for the treatment of B cell malignancies established CAR T cell therapy as an emerging pillar of modern immunotherapy. However, nearly every second patient undergoing CAR T cell therapy is suffering from disease relapse within the first two years which is thought to be due to downregulation or loss of the CAR target antigen on cancer cells, along with decreased functional capacities known as T cell exhaustion.

View Article and Find Full Text PDF

Alfalfa (Medicago sativa L.) is considered to be the most important forage crop on a global scale. Nevertheless, soil salinity significantly decreases productivity, seriously threatening food security worldwide.

View Article and Find Full Text PDF

Light plays an important role in determining plant architecture, which greatly influences crop yield. However, the precise mechanisms by which light signaling regulates bud outgrowth remain to be identified. Here, we show that light regulates bud outgrowth via both HY5 and brassinosteroid (BR)-dependent pathways in tomato.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!